Biograil

Most macromolecule drugs need to be injected to provide biologic effect. Pharmaceutical companies have tried to transform injectables into convenient oral capsules and tablets that overcome the absorption barrier in the intestinal tract over decades, but with limited success. Injections are associated with risk of local reaction, needle fear and pain. Biograil’s novel technology is a capsule that contains a simple and cost-efficient device for delivery of drugs into the gut wall, providing an efficient, environmental friendly and convenient option for oral drugs which otherwise needs to be injected.
Karsten Lindhardt about Verve Ventures
Verve Ventures has helped Biograil in the early stages of the company sharing the vision of replacing injections with an oral capsule supporting the team and the technology finding investors to help us in solutions for the "holy grail" of drug delivery.
Founders / Management Karsten Lindhardt, Nikolaj Skak
Sectors Health & Bio, Pharma
Located in Denmark
Co-Investors Megatrend Invest, High-Tech Gründerfonds, Sanner Ventures, Evonik Venture Capital
Follow On

LinkedIn

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.